Nektar Therapeutics (NASDAQ:NKTR - Free Report) had its target price lifted by BTIG Research from $60.00 to $100.00 in a report issued on Tuesday, MarketBeat reports. They currently have a buy rating on the biopharmaceutical company's stock.
A number of other research firms have also recently commented on NKTR. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price on the stock in a research report on Friday, March 14th. HC Wainwright upped their price objective on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a report on Tuesday. Jefferies Financial Group raised shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and increased their price objective for the stock from $15.00 to $30.00 in a research report on Friday, April 11th. Wall Street Zen lowered Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. Finally, William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $76.43.
Check Out Our Latest Stock Report on NKTR
Nektar Therapeutics Stock Performance
Shares of NKTR stock traded up $4.67 on Tuesday, hitting $29.12. 26,009,086 shares of the stock traded hands, compared to its average volume of 400,314. Nektar Therapeutics has a twelve month low of $6.48 and a twelve month high of $37.01. The firm's 50-day moving average price is $10.79 and its two-hundred day moving average price is $12.05. The stock has a market capitalization of $361.38 million, a PE ratio of -3.03 and a beta of 0.55.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The business had revenue of $10.46 million during the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter in the prior year, the firm earned ($2.70) EPS. On average, equities research analysts anticipate that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.
Institutional Trading of Nektar Therapeutics
Several hedge funds have recently modified their holdings of NKTR. Nantahala Capital Management LLC grew its stake in Nektar Therapeutics by 90.0% during the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company's stock worth $7,263,000 after purchasing an additional 3,700,000 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Nektar Therapeutics by 1.4% in the first quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company's stock valued at $4,961,000 after acquiring an additional 100,645 shares in the last quarter. Woodline Partners LP lifted its stake in Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company's stock worth $4,626,000 after acquiring an additional 3,242,841 shares during the last quarter. Almitas Capital LLC grew its holdings in Nektar Therapeutics by 401.1% during the 1st quarter. Almitas Capital LLC now owns 4,610,872 shares of the biopharmaceutical company's stock worth $3,135,000 after acquiring an additional 3,690,647 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Nektar Therapeutics by 17.5% during the fourth quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock worth $3,637,000 after purchasing an additional 583,153 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
